take today earn
 print showcas strength core busi
covid headwind weigh result vari
degre impact less initi model face
book headwind undergo busi transform
highlight
 first three distributor report earn
abc core pharma distribut volum expect cadenc
earn remaind year key group sentiment
manag lower guidanc rang account busi slowdown overal
distribut busi resili fear rais price target
lockdown result pull-forward demand
pharma segment distribut segment
anim expect result pent-up demand
recal year-end septemb guidanc
incorpor potenti second surg covid case
 outperform peer revenu growth book bill
perform depend pace recoveri strong book growth
provid visibl revenu growth environ normal rais price
target
book bill highest past quarter benefit covid
relat project includ award sever dozen bid
process lab segment organ growth acceler y/i benefit
strong book rapid custom uptak new facil expans
gmp lab increas fte contract vaccin lab clinic revenu
growth outpac cro peer averag
covid headwind meaning less expect clinic
servic backlog half site impact covid relat
trial paus importantli clinic revenu total
tie monitor convert remote-bas
approach sponsor look integr similar modal
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
charl river upgrad share back march thesi
preclin busi rel resili covid pressur discuss
call confirm view moreov manag see sign trial
sponsor look outsourc rais price target
safeti assess prove resili biopharma client
reduc in-hous site activ increasingli reli
outsourcing/remot facil prefer work fewer partner
rm lag academ institut shut manag expect
meaning recoveri north america europ begin base
client inquir readi research model
return work
capit deploy hold watch
manag resum activ core growth strategi
allscript miss increas uncertainti around pace recoveri
manag optimist hospit client resum spend time
support stimulu fund busi review led alixpartn yield cost
save opportun quantifi million annual potenti
read thru healthcar compani
regard elect procedur becton survey
top account indic custom want begin resum
elect earli june commentari suggest recoveri
region area texa thing begin open back
like see elect ramp back could back
elect hernia other remain lock could still run
drop regard test manag seek increas
demand test particularli hospit look begin elect
procedur posit quest labcorp data point
april suggest non-covid diagnost test specimen collect
revenu largest impact us
manag expect peak impact
occur return stabl busi environ
minim impact onward compani plan
clinic trial activ resum year end local countri
restrict lift fulli recruit trial lower risk
bausch health data point present suggest visit
dermatologist eye care doctor gastroenterologist
us manag expect physician work backlog
procedur cataract surgeri though
address dental procedur manag expect
appoint teeth clean perman lost year
telemedicin compani cite doctor visit done
via telemedicin vs
slide outlin manag expect
brand gener inject drug covid impact brand drug
compani expect revenu declin gradual increas demand
overal revenu expect declin y/i gener drug
full year revenu also expect declin y/i lower capac
product priorit may caus suppli decreas certain lower margin
product delay product launch lastli inject
compani expect y/i growth full year revenu higher
util channel stock subsequ period destock
channel return pre-covid purchas level
top-line guidanc lower compani expect covid result deceler
pharma segment top-line ebit revenu guidanc lower
lsd-msd growth msd-hsd growth prior impli
billion ebit guidanc lower lsd-msd growth msd growth
prior impli million pharma segment ebit guidanc lower lsd-
msd growth msd growth prior segment ebit guidanc lower
lsd declin hsd growth prior
anticip lockdown june-quart like result pull-forward volum
march-quart well delay revenu expect
return september-quart volum saw pull-forward pharma
segment distribut well segment anim health distribut howev
given increas oper expens associ increas volum
materi contribut ep beat quarter
new ep guidanc prior
estim result result quarter share repurchas
expect remaind year contribut addit
offset trend includ expect deceler pharma
segment ebit segment ebit pose headwind ep
manag expect ep double-digit rang ep
return y/i growth
model estim chang decreas
revenu estim billion billion reflect
new guidanc lsd-msd growth y/i ep estim
increas reflect new mix
busi updat model estim lower-margin
servic distribut
charl river laboratori
model estim chang updat base case revenu
ebitda estim reflect result manag updat guidanc
estim revenu growth vs prior
rais revenu growth estim in-line manag guidanc
midpoint compar prior estim base case estim
base gradual resumpt pace trial start in-line ppd
recoveri pace china increas base case estim reflect strong book
bill increas demand covid-rel drug develop program off-set
near-term headwind underscor opportun environ normal
rais ebitda estim million prior million ep
increas prior lower revenu growth
prior ebitda growth reflect higher
base ep goe prior reflect share count upsid
estim activ vaccin covid relat program success
estim revenu growth vs prior
reflect beat in-line updat manag guidanc midpoint
rais ebitda estim prior ep estim
increas prior updat manag guidanc
midpoint revenu growth unchang in-line compani
target high singl digit growth rais ebitda estim million
prior million fy ep slightli increas prior upsid
estim activ vaccin covid relat program success
exhibit estim chang
mm except per share
compani pull guidanc remaind manag provid
help color think remaind year two main
point consid recur revenu total expos patient
volum fluctuat non-recur revenu total could declin new
deal implement associ servic push two
trend result million revenu headwind manag uncertain
whether would pent-up demand post-pandem note volum
could declin y/i june
margin improv busi transform allscript contract
alixpartn outsid consult firm help busi transform margin
improv goal compani identifi million annual cost save
million per quarter commit ebitda margin accret goal bp
achiev furthermor compani match cost
revenue/volum within servic line ensur margin less volatil
quarter quarter also identifi non-strateg asset futur
robust demand path margin expans deliv target
dcf analysi use wacc perpetu growth rate
charl river market leader
recent acquisit expand
portfolio offer upstream expand
tradit preclin toxicolog
margin may improv cost-cut
initi new open capac
competit share may limit price
view descript risk reward theme
impli price-to-earnings bull case ep
top-line growth higher
end target termin growth
oper margin expans
anoth bp expans
impli price-to-earnings base case ep
estim revenu growth
reect beat in-line
updat manag guidanc midpoint
rais ebitda estim
prior ep
estim increas
updat manag guidanc midpoint
revenu growth in-line
compani target high singl digit
growth rais ebitda
estim million
impli price-to-earnings bear case ep
top-line growth
year growth target termin growth
-no oper margin expans
given initi invest integr
cost post acquisit margin
expans
strateg agreement larg pharma
view explan region hierarchi
research highest favor quintil
research model demand decreas faster
develop growth fail materi
integr acquisit expans
discoveri outsourc prove
challeng anticip
research model demand improv time
acceler top-line growth contribut
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
valu p/ebasi use direct cro peer group iqvia icon
comp
third largest pure-play contract
patient enrol model global
site network address pain point
clinic trial process
expans fast grow laboratori
servic continu favor biotech
fund environ support
annual top line growth next three
year outpac market
provid opportun de-lever
assum top-line
acceler
respect backlog
convers rate improv
anoth
look high growth cro
medpac cmo lonza
estim revenu growth
vs prior rais revenu
growth estim in-line
manag guidanc midpoint
compar prior estim
increas base case estim reect
strongbook bill increas demand
covid-rel drug develop
program off-set near-term
headwind underscor opportun
revenu growth ebitda growth
view descript risk reward theme
assum top-line growth
slow low singl digit
backlog convers rate decreas
anoth
compar look lab compani
lh slower growth prole
book ratio
book ratio
china india
view explan region hierarchi
research highest favor quintil
compani success delev strong
fund environ improv
time remain healthi
contract loss backlog converst rate
compani abl achiev de-lever
biotech compani abil
attract necessari nanc fund trial
loss larg contract
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
lt growth depend veradigm acquisit off-set core declin
dcf-base price target use wacc mid-term growth termin growth
impli bull case ep
top-line growth rate
top-line growth rate
 contribut
 contribut
growth rate remain rang
organ termin
growth rate also assum
ebitda margin expand
compani achiev deal synergi
impli base case ep
top-line growth rate
top-line growth rate
compani organ growth rate
compani organ growth rate
continu rang
continu rang
add addit
add addit assum mid-term
growth rate organ
 termin growth rate
ebitda margin reach rang
mid-term compani achiev
deal synergi make addit
invest adjac product area
allscript diversi hcit vendor
provid market hospit physician
practic core busi
revenu veradigm payor life
scienc smaller revenu
faster-grow segment
given underli fundament
industri see challeng achiev
growth rate base continu
declin client attrit
invest requir support growth
veradigm busi
strateg review portfolio underway
updat expect analyst day
view descript risk reward theme
impli bear case ep
top-line growth rate
top-line growth rate
compani organ growth rate
compani organ growth rate
continu deceler partial off-set
continu deceler partial off-set
 assum mid-term growth rate
fall termin growth rate
ebitda margin fall rang
compani make invest
adjac product area
quarterli result focu book
china india
view explan region hierarchi
research highest favor quintil
re-acceler provid budget spend
expans wallet share among core
greater expect contribut
increas deal synergi oper
contract provid budget
deceler veradigm revenu growth
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
market leader specialti balanc risk-reward
wacc addit assum global opioid litig settlement
estim respons
second largest
drug wholesal us largest
specialti distributor posit benet
grow specialti pipelin
among distributor
highest revenu exposur higher-growth
higher-margin specialti
opioid liabil continu
distribut agreement
walgreen largest custom provid
compani long term revenu
visibl sourc benet
greater scrutini brand inat
gener deation limit new product
introduct like continu weigh
growth prole forseeabl futur
thomson reuter morgan stanley research morgan stanley institut equiti divis probabl
bull base bear case scenario play estim impli volatil data option market
may gure approxim risk-neutr probabl stock reach beyond scenario
price either three-month one-year time view explan option probabl methodolog
view descript risk reward theme
ebitda excl opioid
assum brand inat goe hsd
gener inat lsd global opioid
liabil lower sell-sid discount
custom higher top-line growth
gross margin specialti
impli multipl in-lin max forward
ev/ebitda multipl past year
ebitda excl opioid
assum brand inat remain lsd-
msd gener deation lsd global
opioid liabil
impli multipl modestli
averag forward ev/ebitda multipl
past year
ebitda excl opioid
assum brand inat goe zero
opioid liabil higher sell side
discount custom lower top-line
growth gross margin specialti
impli multipl in-lin min forward
ev/ebitda multipl last year
drug price increas particularli januari
gener manufactur commentari gener
news ow opioid litig settlement
increas brand inat
acceler growth specialti drug
distribut servic
signic slowdown brand inat
deterior gener price deation
continu price pressur margin eros
increas opioid legal settlement payment
view explan region hierarchi
research highest favor quintil
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
